• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Following first profitable quarter, Vericel’s CEO looks to grow portfolio of autologous cell therapy products

April 26, 2018 By Sarah Faulkner

vericelIn its latest financial results, Cambridge, Mass.-based Vericel (NSDQ:VCEL) saw sales climb 60% for its permanent skin-replacement product, Epicel, designed for patients with severe burns. Sales for its autologous cellular scaffold, Maci, were up 20% following its launch to the commercial market.

Vericel’s growing product adoption helped to fuel the company’s first profitable quarter, according to CEO Nick Colangelo.

“Both products are the only FDA-approved products in their class and they’re highly efficacious,” he told Drug Delivery Business News.

Maci is the first FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. In a Phase III extension study of 128 patients, Vericel found that the pain and function improvements seen in a previous late-stage trial were maintained after five years for participants treated with Maci compared to microfracture.

“In this space, you want to make sure that you have a product that actually provides long term durability of repair,” Colangelo explained.

The company was also working on an autologous cell therapy product to treat patients with cardiac myopathy, but was told by the FDA that it needed to conduct another clinical trial if it wanted to land regulatory clearance. Vericel needed to make a strategic decision, according to its chief executive.

“We had a fast growing commercial business and that’s where we’re going to invest because we believe that will generate the greatest value for our company. What we’ve stated publicly is that we will not be moving that program forward in the absence of funding from either a partnership or other sort of financing,” Colangelo said.

Vericel is betting on the future of cell therapies, but its CEO noted that the industry is just beginning to grapple with the issue of pricing. He pointed towards medicines like Novartis‘ (NYSE:NVS) Kymriah, a CAR T-cell therapy, which sports a $425,000 price-tag.

“So the question really becomes is how sustainable is a model when the price points have reached that level,” Colangelo said.

Vericel declined to clarify the exact cost of Maci or Epicel, but described them both as “premium-priced products”.

To help ensure that people who want their cartilage repaired with Maci can access the implant, Colangelo said the company has worked to win reimbursement across various commercial insurance plans.

“These plans look at the clinical data when they make decisions around covering the product. There’s a lot of evidence out there that this is an effective product for patients. It all starts with having compelling clinical data and that’s what allows you to get the coverage,” he added.

Looking ahead, Colangelo is optimistic about the path forward – he characterized the company as “one of the leading cell therapy manufacturers and commercial entities in the country.”

“We feel like we’re in early innings in terms of growth in our current product portfolio,” he said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Implants, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Novartis, Vericel Corp

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS